Integration Communications’ Post

This report by Anapaula Themann, Sergio Iñiguez and Minerva Rodriguez explores how chlordiazepoxide, a common anti-anxiety med, affects behavior in juvenile mice. 🐭 After a single dose, mice spent more time in the open arms of an elevated plus maze—showing reduced anxiety-like behavior. 🧐 #Neuroscience #BehavioralResearch #Anxiety #Benzodiazepines Learn more on: https://lnkd.in/dwTC3G-b

📣 Big Announcement! 📣 SETBP1 Society launched a NEW FUNDING 💲💲 OPPORTUNITY for RESEARCHERS: SETBP1-HD Microgrant Program! We are calling all researchers 🔬 interested in rare neurodevelopmental disorders, transcription factor regulation, disease mechanisms, and drug repurposing. Letters of Intent are due by August 2nd. Learn more about this unique funding opportunity and Submit your Letter of Interest - https://lnkd.in/giQxqGRn Check out how the areas of interest for this SETBP1-HD Microgrant launch were selected - https://lnkd.in/gg6A8bBU #SETBP1Strong #RNAsequencing #NeurodevelopmentalDisorder #GrantFunding #DevelopmentalDisabilities #Neuroscience #ChromatinRemodeling #TranscriptionFactors

Celine Dion's contribution to autoimmune neurology sheds light on the importance of research and education in rare neurological disorders like stiff-person syndrome. To support advancements in health, consider donating to foundations or organizations that focus on autoimmune conditions. By contributing, you can help drive critical research efforts and improve outcomes for those impacted by complex diseases. #AutoimmuneNeurology #RareConditions #HealthResearch #SupportHealthInitiatives #NeurologicalDisorders BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X. Read more about this post here: https://lnkd.in/eSVhZFyy

🧠 Numerous studies and statistical reports have shown that the prevalence of anxiety-related disorders (Generalized Anxiety Disorder, PTSD, OCD, Phobias…) has been increasing over recent years. Current treatments are insufficient to alleviate anxiety symptoms because of their lack of effectiveness or potential side effects in part due to their poor specificity. At Neuroservices-Alliance, we offer preclinical models of anxiety-related disorders developed by our expert platform OptoPath, allowing to capture specific aspects of anxiety-related conditions. Are you currently developing drugs targeting anxiety-related disorders? Reach out to contact@neuroservices-alliance.com for more information on our Fear & Anxiety preclinical models. Visit https://lnkd.in/d8nwugqV for more information. #Anxiety #research #Neuroscience #CNS #CRO

In the latest episode of the Mind Gut Conversation podcast, I speak to Dr. RIMA Kaddurah- Daouk, who currently leads and coordinates an international multi-center research consortium, the Alzheimer’s Disease Metabolomics Consortium or ADMC, which consists of more than 120 scientists from over 30 academic institutions. She has published over 140 peer-reviewed scientific publications, leads a large number of active NIH grants, and ranked as the highest-funded researcher in psychiatry departments nationally in 2018. Dr. Kaddurah has more than 60 patents or patent applications for using metabolomics to diagnose and treat brain diseases. Topics we discuss in this podcast include: - What are the major scientific breakthroughs in our understanding of AD that have come from the ongoing research of The National Institutes of Health AD consortium? - The scientific approach on which the AD grant is based is radically different from the classical reductionistic biomedical research strategy and is based on systems biology and the paradigm of interconnectedness. Based on the lack of progress in effective treatments for AD to date, do you believe this new approach has a better chance of success? - Are there any new therapeutic strategies emerging from this new research? You can find the episode in all formats by going to: https://lnkd.in/gWC4qCHr #mindgutconnection #podcast #alzheimers #NIH #research #ketodiet

Psychedelics like psilocybin, LSD, and MDMA may help protect the brain from some aspects of aging, showing promise in improving executive functions and reducing depressive symptoms. While more rigorous studies are needed, these findings could pave the way for innovative treatments for age-related cognitive decline. #Psychedelics #AgingBrain #MentalHealth #Neuroscience #Innovation #Psilocybin - Kallol Kumar Bhattacharyya, Kaeleigh Fearn Carly Cassella for ScienceAlert 👇 https://lnkd.in/g7iNYDcn

🗣 Let's keep FND research flowing!💡 The Tremor Retrainer Software Application for Functional Tremor: Pilot Study, led by Jordan Garris, MD 🧠 The UVA Health System Department of Neurology seeks children and adults ages 10 and older with a diagnosis of functional tremor for a research study. The purpose of the research study is to evaluate ease of use for a smartphone-based intervention called “Tremor Retrainer” is for patients with functional tremor. The study involves a one week of at-home smartphone-based intervention and 4 visits to UVA lasting 60-90 minutes each. These will occur weekly for 3 weeks and then once again 3 months later. Study-related exams and intervention provided free of change. No compensation is provided for this study. Patients will be reimbursed for travel expenses up to $50 per study visit. For more information please contact: Hannah Caballero, Clinical Research Coordinator 434-297-5711, HTP5AW@uvahealth.org IRB-HSR # 230161 Our research 📚 section on the website is a great way for FND researchers to highlight their project. It is also of interest for people interested in research to find out what projects are currently happening in the field of FND! 🔔 If you want to find out more about any of the studies please check out the research section on our website: https://lnkd.in/e-WYFbfU

🍄 Magic Mushrooms: From Recreation to Healing the Brain 🧠 Exciting neuroscience research reveals the potential of synthetic psilocybin and psychedelic mushroom extracts (PME) for treating psychiatric disorders. Our team at Human Metabolome Technologies (HMT) proudly conducted the metabolomics for this revolutionary study. Key Findings: 1. Enhanced Synaptic Plasticity: PME shows a more potent and prolonged effect compared to synthesized psilocybin alone. 2. Differential Metabolic Effects: Distinct metabolic profiles suggest varying impacts on brain health and oxidative stress. Congratulations to Tzuri Lifschytz and the team on this excellent work! Special thanks to our VP of Business and Product Development, Alex Buko, who helped with data analysis and is a co-author of the paper. 📊 Explore how the science of magic mushrooms could revolutionize mental health treatment. Stay tuned for more updates from HMT! #Psilocybin #MentalHealth #Neuroscience #BrainResearch #Psychedelics #Metabolomics #Research #Innovation #HumanMetabolomeTechnologies

You know that industry is considered seriously when Forbes starts to mention it As we approach the 2024 Interdisciplinary Conference on Psychedelic Research (#ICPR2024) in The Netherlands, it's exhilarating to witness the convergence of global experts who are shaping the future of psychedelic medicine. This pivotal event, happening June 6-8, promises to be a melting pot of ideas with leading minds from psychiatry, neuroscience, anthropology, and more. https://lnkd.in/gnrH8Gwx Psychedelic therapy, once on the fringes of science, is now at the forefront of promising treatments for complex conditions such as PTSD and addiction. This conference, organized by the OPEN Foundation since 2010, is not just for medical professionals but is open to the public, reflecting a transparent approach to demystifying psychedelic research. Key figures like Bob Jesse and Bill Richards from Johns Hopkins Center for Psychedelic and Consciousness Research Hopkins, who have been instrumental in the psychedelic renaissance, will be speaking alongside Rick Doblin of Multidisciplinary Association for Psychedelic Studies (MAPS), who is nearing the culmination of a 38-year journey to bring MDMA-assisted therapy to regulatory approval. This gathering is more than just a conference; it’s a glimpse into the future of healthcare, where interdisciplinary efforts meet to discuss, debate, and share insights that could redefine mental health treatment. Whether you’re a seasoned professional in the field or an intrigued observer, ICPR 2024 offers a unique opportunity to engage with the cutting-edge of medical science. For those interested in how traditional boundaries in medicine are being expanded through innovative therapies, this event is a must-attend. Let’s stay informed and inspired by these groundbreaking developments in psychedelic medicine. Hope to see many of you there!

The clock is ticking till the biggest event in Psychedelic world in EU starts in Netherlands. It's your chance to see and hear firsthand the latest research around #psychedelics and their application in therapeutic context to treat mental illnesses